1. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Issue 11 (7th April 2006) Authors: Van Assche, G; Sandborn, W J; Feagan, B G; Salzberg, B A; Silvers, D; Monroe, P S; Pandak, W M; Anderson, F H; Valentine, J F; Wild, G E; Geenen, D J; Sprague, R; Targan, S R; Rutgeerts, P; Vexler, V; Young, D; Shames, R S Journal: Gut Issue: Volume 55:Issue 11(2006) Page Start: 1568 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗